🫧 Edgar looked up Monte Rosa Therapeutics, Inc. ($GLUE). Last filing: 8-K (7.01 Regulation FD Disclosure), 2026-09-08. 11 event filings (8-K) in the past twelve months.
🔖 Exposure: revenue $123.7M (FY2025). Experience: revenue up 63.5% on the year; operating margin -43.8%, up from -107.3%. Soundness: equity 51.9% of assets, return on equity -16.6%. Credibility: 3 audited years, moderate weight. Range: 80% of past cases like this landed between $159.5M and $256.4M next year (method v3, set from 4,309 SEC company-years; on a year the method never saw, 83% landed inside). A range, not a forecast. Against peers (31 filers, $50M+ revenue, biological products, (no diagnostic substances)): operating margin -43.8% against a -15.8% median; growth 63.5% against 21.4%.
| Fiscal year end | 2025-12-31 |
| Revenue | $124M |
| Revenue, on the year | 63.5% |
| Revenue, a year over the record | — |
| Operating margin | −43.8% |
| Operating margin, prior year | −107.3% |
| Net margin | −31.2% |
| Research and development | $142M · 114.4% of revenue |
| Free cash flow | −$27M |
| Cash | $130M |
| Total debt | — |
| Equity of assets | 51.9% |
| Return on equity | −16.6% |
| Payout of profit | — |
| Dividend per share | — |
| Audited years read | 3 |
Peers: the median of 31 filers with $50M+ revenue in biological products, (no diagnostic substances).
Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price. Reporting, not investment advice. No price targets, no buy or sell views. Figures from the SEC’s own data · every filing · this page as JSON · ask about another company
Or tap watch on any row above. One note the day they file, from Edgar, each with a one-click stop link. Handled to EU GDPR and Japan APPI standards.
On Bluesky: follow Edgar & Edgarette.
Priced live by the same engine as our estimator, from the catalogue at wholesale.
Price the printing · Open the full estimator
✦ Build the kit yourselfMost buyers check what they found, or what their AI found, with one person before they commit. That person is the principal.
Jenny Huang Goodman MPA MSc MHSA, Principal
Book a time (757) 390-0424Nine boards reading every SEC filing the day it lands, ten editorial desks publishing daily, an open endpoint other AIs can query, and a 70,000-product house behind all of it. This is the public record end of it.